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INTRODUCTION 
A large number of active pharmaceutical compounds 
currently under development are poorly water soluble, a 
characteristic which can limit their bioavailability and 
results in formulation challenges1,2. Strategies to address 
the problem encompass the conversion of a crystalline 
drug into an amorphous form to promote its apparent 
solubility and dissolution, thus resulting in a likely 
increase in bioavailability3. An amorphous solid exhibits 
high internal energy and enhanced molecular mobility, 
leading to higher reactivity, resulting in thermodynamic 
instability as compared to their crystalline counterparts1,2. 
The production of co-amorphous systems has added 
value to the co-crystallization and amorphization of drugs 
by enhancing the advantages of both strategies to increase 
the apparent solubility of a drug. These systems 
incorporate low molecular mass molecules as co-formers, 
which are mixed with the drug at the molecular level to 
form one single co-amorphous phase1-4. 
Co-amorphous systems can be prepared by several 
methods based on two main different forming 
mechanisms: either thermodynamic or kinetic disordering 
processes. The thermodynamic processes consider melt 
quenching, precipitation from a solution and solvent 
evaporation methods whereas the kinetic processes 
consider the mechanical activation processes (e.g. 
milling)1,3. In thermodynamic processes (e.g. melt 
quenching), the drug moves from a thermodynamically 
stable form, into a disordered form. During this process, a 
sufficiently fast cooling rate has to ensure that the 
amorphous state is maintained by refraining nucleation 
and crystal growth processes. Alternatively, in kinetic 
processes, mechanical activation has to induce defects 
into the crystal lattice of the crystalline drug, i.e., entropy 
increases, until the amorphous state is obtained1.  
The aim of this study is to produce co-amorphous 
mixtures of olanzapine, using amino acids as co-formers, 
by milling, solvent evaporation and quench cooling of 
molten systems. 
MATERIAL AND METHODS 
Olanzapine (OLZ; 312.43g/mol) was obtained from 
Vega Pharma (China), micronized indomethacin (IND; 
357.7g/mol) from Capsifar (Portugal), L-tryptophan 
(TRY; 174.20g/mol) and L-arginine (ARG; 203.23g/mol) 
from BioChemica AppliChem (Spain); citric acid (CA; 
192.12g/mol), tartaric acid (TA, 150.09g/mol), oxalic acid 
(OA; 90.03g/mol) and solvents (methanol, ethanol, ethyl 
acetate, dichloromethane and diethyl ether) from Sigma 
Aldrich (Germany) and nitrogen from Air Liquide 
(Portugal).  
Milling 
Drugs were milled with each of the amino-acids or 
the carboxylic acids (molar ratio 2:1, 1:1 and 1:2), in a 
ball mill (Retsch, PM 100, Germany) with 8, 3mm balls, 
at 650rpm, for 12h. 
Quench cooling 
Mixtures (molar ratios as above) of molten drugs 
and amino acids or carboxylic acids were quench cooled 
in aluminum beakers. The melting temperature for each 
mixture was set at 220˚C. Each sample was kept in the 
liquid state for 5 min to ensure complete melting with 
formation of a single liquid phase. Each sample was 
subsequently quenched with liquid nitrogen.  
Solvent evaporation 
Drug and the excipients (molar ratios as above) were 
dissolved in organic solvents (e.g. dichloromethane) prior 
to slow evaporation. 
Characterization of the samples 
Samples were characterized by calorimetric analysis 
(DSC). Thermograms were obtained with a differential 
scanning calorimeter (TA Instruments, Q200, USA) after 
calibration with indium (TA Instruments, USA; 
Tm=156.55, ΔHm=28.51 J/g) and nitrogen (50mL/min) as 
the purge gas. Samples (3-5mg) were placed in 
hermetically sealed crucibles and subjected to heating and 
cooling cycles at a rate of 10˚C/min, within the range of  
-40 to 250˚C. 
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RESULTS AND DISCUSSION 
Results have shown that OLZ and IND could be 
converted into the amorphous state. Quench cooling 
presented the most promising results whereas milling 
conditions do not seem to be sufficient to produce 
amorphous drugs. Equally, blends of drug:co-former were 
amorphous by quench cooling, but not after milling. 
 
 
Figure 1. Thermogram of olanzapine and L-tryptophan 
obtained by quench cooling 
–OLZ (raw material) –TRY (raw material) –OLZ (amorphous) 
–TRY(amorphous) –OLZ:TRY(1:2) –OLZ:TRY(1:1) –OLZ:TRY(2:1) 
 
Figure 1 shows a set of typical thermograms 
obtained for the different materials: OLZ, TRY (raw 
material) OLZ, TRY (amorphous) and OLZ:TRY, at 
different molar ratios, after quench cooling. The best co- 
-amorphous system was obtained at a 1:2 ratio (lower 
thermogram, with a  glass at Tg=44.01ºC). 
 
 
Figure 2. Thermogram of indomethacin and citric acid 
obtained by quench cooling. 
 –IND (raw material) –CA (raw material) –IND (amorphous) –CA 
(amorphous) –IND:CA(1:1) –IND:CA(1:2). –IND:CA(2:1) 
 
 
Figure 2 represents a set of typical thermograms for 
IND and CA as raw materials and IND:CA (1:1),  
produced by quench cooling. In the lower thermogram the 
formation of a single glass transition (Tg=33.20ºC), a 
recrystallization (T=76.39ºC / ΔH=54.84J/g) and melting 
(T=142.43ºC / ΔH=72.72J/g) is observed, suggesting that 
this co-amorphous system (IND:CA; 2:1) was not stable 
at higher temperatures. 
CONCLUSION 
The study has shown the possibility of converting a 
crystalline drug into a less crystalline or amorphous 
entity, particularly when in presence of co-formers that 
help on stabilizing the amorphous structures formed. 
Certainly the conversion of crystalline drugs into the 
amorphous state is dependent on their chemical structures 
and interactions with other chemical entities.  
The properties of drug and co-formers (e.g. melting 
point or crystallization tendency) are critical to select the 
preparation method. In this work quench cooling was 
better than solvent evaporation and better than milling. 
Since the potential to form co-amorphous systems 
has been confirmed, both formulations and process 
methods are currently being optimized, to fulfill the 
promise of minimizing solubility issues of drugs. 
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